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G E N E T I C S
Histone H3.3 beyond cancer: Germline mutations in 
Histone 3 Family 3A and 3B cause a previously 
unidentified neurodegenerative disorder in 46 patients
Laura Bryant1*, Dong Li1*, Samuel G. Cox2, Dylan Marchione3, Evan F. Joiner4, Khadija Wilson3, 
Kevin Janssen3, Pearl Lee5, Michael E. March1, Divya Nair1, Elliott Sherr6, Brieana Fregeau6, 
Klaas J. Wierenga7, Alexandrea Wadley7, Grazia M. S. Mancini8, Nina Powell-Hamilton9, 
Jiddeke van de Kamp10, Theresa Grebe11, John Dean12, Alison Ross12, Heather P. Crawford13, 
Zoe Powis14, Megan T. Cho15, Marcia C. Willing16, Linda Manwaring16, Rachel Schot8, 
Caroline Nava17,18, Alexandra Afenjar19, Davor Lessel20,21, Matias Wagner22,23,24, 
Thomas Klopstock25,26,27, Juliane Winkelmann22,24,27,28, Claudia B. Catarino25, Kyle Retterer15,  
Jane L. Schuette29, Jeffrey W. Innis29, Amy Pizzino30,31, Sabine Lüttgen32, Jonas Denecke32,  
Tim M. Strom22,24, Kristin G. Monaghan15; DDD Study, Zuo-Fei Yuan3, Holly Dubbs30,31, 
Renee Bend33, Jennifer A. Lee33, Michael J. Lyons33, Julia Hoefele24, Roman Günthner34,35, 
Heiko Reutter36, Boris Keren18, Kelly Radtke37, Omar Sherbini30,31, Cameron Mrokse37,  
Katherine L. Helbig37, Sylvie Odent38, Benjamin Cogne39,40, Sandra Mercier39,40, Stephane Bezieau39,40, 
Thomas Besnard39,40, Sebastien Kury39,40, Richard Redon40, Karit Reinson41,42, Monica H. Wojcik43,44, 
Katrin Õunap41,42, Pilvi Ilves45, A. Micheil Innes46, Kristin D. Kernohan47,48; Care4Rare Canada 
Consortium, Gregory Costain49, M. Stephen Meyn49,50, David Chitayat49,51, Elaine Zackai52, 
Anna Lehman53, Hilary Kitson54; CAUSES Study, Martin G. Martin55,56, Julian A. Martinez-Agosto57,58; 
Undiagnosed Diseases Network, Stan F. Nelson57,59, Christina G. S. Palmer57,60, Jeanette C. Papp57, 
Neil H. Parker61, Janet S. Sinsheimer62, Eric Vilain63, Jijun Wan57, Amanda J. Yoon57, Allison Zheng57, 
Elise Brimble64, Giovanni Battista Ferrero65, Francesca Clementina Radio66, Diana Carli65, 
Sabina Barresi66, Alfredo Brusco67, Marco Tartaglia66, Jennifer Muncy Thomas68, Luis Umana69, 
Marjan M. Weiss10, Garrett Gotway69, K. E. Stuurman8, Michelle L. Thompson70, Kirsty McWalter15, 
Constance T. R. M. Stumpel71, Servi J. C. Stevens71, Alexander P. A. Stegmann71, Kristian Tveten72, 
Arve Vøllo73, Trine Prescott72, Christina Fagerberg74, Lone Walentin Laulund75,  
Martin J. Larsen74, Melissa Byler76, Robert Roger Lebel76, Anna C. Hurst77, Joy Dean77,  
Samantha A. Schrier Vergano78, Jennifer Norman79, Saadet Mercimek-Andrews49, Juanita Neira80, 
Margot I. Van Allen53,81, Nicola Longo82, Elizabeth Sellars83, Raymond J. Louie33, Sara S. Cathey33, 
Elly Brokamp84, Delphine Heron18, Molly Snyder85, Adeline Vanderver30,31, Celeste Simon4, 
Xavier de la Cruz86,87, Natália Padilla86, J. Gage Crump2, Wendy Chung88, Benjamin Garcia2,3,  
Hakon H. Hakonarson1, Elizabeth J. Bhoj1†
Although somatic mutations in Histone 3.3 (H3.3) are well-studied drivers of oncogenesis, the role of germline 
mutations remains unreported. We analyze 46 patients bearing de novo germline mutations in histone 3 family 
3A (H3F3A) or H3F3B with progressive neurologic dysfunction and congenital anomalies without malignancies. 
Molecular modeling of all 37 variants demonstrated clear disruptions in interactions with DNA, other histones, 
and histone chaperone proteins. Patient histone posttranslational modifications (PTMs) analysis revealed notably 
aberrant local PTM patterns distinct from the somatic lysine mutations that cause global PTM dysregulation. RNA 
sequencing on patient cells demonstrated up-regulated gene expression related to mitosis and cell division, and 
cellular assays confirmed an increased proliferative capacity. A zebrafish model showed craniofacial anomalies 
and a defect in Foxd3-derived glia. These data suggest that the mechanism of germline mutations are distinct 
from cancer- associated somatic histone mutations but may converge on control of cell proliferation.
INTRODUCTION
The study of histones and their role in epigenetics is a rapidly ex-
panding field. Histones are nuclear proteins that associate with DNA 
to facilitate packaging into condensed chromatin. Histones are dynam-
ically decorated with posttranslational modifications (PTMs), which 
regulate these processes as DNA repair, gene expression, mitosis, 
and meiosis. Dysregulation of PTMs leads to cancer, neurodevelop-
mental syndromes, psychiatric disorders, and even cardiovascular 
disease (1–4). The vast array of diseases that stem from histone dys-
regulation makes understanding histone biology vital to under-
standing the pathophysiology of many diseases and developing 
treatments. Histones are highly evolutionarily conserved, and only 
a few germline disease-causing variants in the histones themselves 
have been found (5). Rather, most disease-causing variants affecting 
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histone regulation are found in histone-modifying proteins or histone 
chaperones. Somatic mutations in histone H3.3 (H3.3), encoded by 
both H3F3A and H3F3B, have recently been identified in pediatric glia 
and other tumors. This discovery revolutionized the field of epigenetic 
changes in tumors and how they lead to cancer progression (6). 
There has been one case report suggesting a relationship between a 
neurodevelopmental syndrome and H3F3A, but no additional patients 
or functional data have been published previously (7). Studying how 
histone mutations cause disease can provide the key to understanding 
how mutations in the histone network lead to disease.
Histone 3 family 3 (H3F3) histones (H3.3) mark active genes, main-
tain epigenetic memory, and maintain heterochromatin and telomeric 
integrity. Every nucleosome contains a version of H3. H3.1 and 
H3.2 are canonical histones that are replication dependent and, 
therefore, added to chromatin only during DNA replication. H3.3, 
however, is a replication-independent variant, which differs from 
the canonical H3.1 and H3.2 by only five and four amino acids, 
respectively (8). H3F3A and H3F3B code for an identical protein 
product, H3.3, a 135–amino acid protein (after cleavage of the first 
methionine) with a histone tail, four  helices, and two loop domains. 
These genes, however, contain different regulatory and coding se-
quences, which lead to different expression patterns and levels for 
H3F3A and H3F3B. Both H3F3B and H3F3A are expressed ubiqui-
tously, during development and throughout life, with relatively 
high levels of expression in the brain, testes, ovaries, and uterus (9).
Because of the biologic importance of H3F3A and H3F3B, their 
orthologs have been studied extensively in multiple model organisms. 
When both H3f3a and H3f3b are knocked out in mice, it causes 
embryonic lethality at embryonic day 6.5, and reduced expression 
leads to sterility, growth retardation, and increased neonatal lethality 
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(10). Disrupting either His3.3A or His3.3B in Drosophila is tolerated; 
however, disrupting both leads to sterility and increased lethality 
(11). While knockout models have been studied in mice and Drosophila, 
germline missense mutations have not. There have been many studies 
in yeast that show the lethality of various missense mutations, but it 
is difficult to infer whether that means missense mutations in humans 
would also have a profound effect (12).
In this work, we have identified a cohort of 46 unrelated patients 
bearing de novo heterozygous germline missense mutations in 
H3F3A or H3F3B with a core phenotype of progressive neurologic 
dysfunction and congenital anomalies. Notably, although all known 
H3.3 mutations in humans cause cancer, none of the patients in our 
cohort have cancer. These mutations are distinct and appear to be 
acting, although it is a completely different pathogenic mechanism 
than the cancer-causing mutations. The mutations are spread through-
out the coding sequence, and neither the location of the mutation 
nor whether the mutation is in H3F3A or H3F3B appears to affect 
the phenotype. The breadth of these previously unidentified disease- 
causing mutations in H3F3A and H3F3B provides evidence for how 
sensitive the neural- related functions of H3.3 are to small variation.
RESULTS
Patient mutations and phenotype
Our patient cohort consists of 46 unrelated patients bearing de novo 
germline missense mutations in H3F3A or H3F3B (Fig. 1). Both 
H3F3A and H3F3B code for H3.3. Therefore, a heterozygous muta-
tion in either gene would affect only about 25% of the total H3.3 in 
the cell, depending on different expression levels from the two genes. 
None of the patients have malignancies, but they share a phenotype 
of developmental delay, usually severe and often progressive, with 
mostly minor congenital anomalies (Table 1). These patients were 
identified through exome or genome sequencing performed for the 
indication of neurodevelopmental delays and/or congenital anomalies 
(Table 1, fig. S1, and table S1). There is substantial phenotypic hetero-
geneity in the patients, and future individuals are likely to be iden-
tified using unbiased molecular testing. Notably, 9 of the 46 patients 
(21%) have demonstrated clinical neurologic degeneration, which 
suggests that this may be a progressive disorder. Multiple patients 
(26% of the cohort) have cortical atrophy on brain magnetic reso-
nance imaging (MRI), even without intractable epilepsy. For example, 
the oldest patient in this cohort (32 years) developed seizures at the 
age of 14 years and a progressive spastic paraparesis starting at the 
age of 29 years.
The severity of the phenotype does not correlate with the loca-
tion of the mutation or whether the mutation is in H3F3A or H3F3B. 
Four unrelated patients have the p.T45I mutation and exhibit the 
full range of the phenotype severity. The age at sitting for patients 
with the p.T45I mutation ranges from 8 months to not achieved within 
4.5 years. The age at walking was 21 months, 2 years, and 3 years 
and not achieved at 4.5 years. One exhibited developmental regres-
sion, while the other three did not, and only one has seizures. Even 
the tone abnormalities are inconsistent with three exhibiting hypo-
tonia, while one has hypertonia. This strongly suggests that the vari-
ation in phenotype is not due to the location of the mutation but 
rather due to either modifying alleles or environmental factors.
Five mutations [H3F3A (NM_002107.4) p.R17G, p.T45I, p.A114G, 
p.Q125R, and H3F3B (NM_005324.4) p.P121R] were detected in two 
or more unrelated patients. p.Q125R was found in H3F3A in three 
individuals and in a different individual in H3F3B, while p.P121R 
was found in H3F3A in one individual and in H3F3B in two other 
individuals. Notably, in two patients, the mutations (H3F3A p.Q125R 
and p.V117L) were identified only by trio genome sequencing after 
negative exome sequencing, as the last exon of H3F3A is currently not 
covered by some exome capture kits. We speculate that similar muta-
tions in H3F3A may be underdiagnosed in current exome studies. 
It should be noted for nomenclature consistency purposes that, histori-
cally, many publications on H3.3 exclude the initiator methionine in 
the residue count. In this publication, we will use the traditional histone 
nomenclature and exclude the first methionine. However, we will in-
clude traditional human genetics nomenclature in the clinical table 
of mutations and include this first residue in the mutation notation.
One mutation in H3F3B (p.S146X) is only present in the alternate 
transcript. It is p.V117V in the canonical transcript. Although the 
mutation is only in the alternate transcript, the patient phenotype is 
consistent with the rest of the cohort, and the patient cells have the 
same phenotype as the other patient cells analyzed. The role of the 
alternate transcript is currently unknown and requires additional study.
These 37 unique missense mutations in 46 patients are all de 
novo and, with one exception (H3F3A c.362 T > A; p.M120K, 1 in-
cidence), are not found in a large database of 138,632 controls, the 
Genome Aggregation Database (gnomAD) (13). Upon closer view 
of the raw data for this p.M120K variant, it may be a technical map-
ping error, as it is only present on one strand and did not meet the 
previous Exome Aggregation Consortium (ExAC) quality control cri-
teria for reporting. In the general population, both genes have a very low 
rate of missense variants; the gnomAD missense Z score is 3.21 for 
H3F3A and 2.95 for H3F3B (>2 is significant) (13).
Computational modeling of patient mutations
It is likely that these variants are pathogenic through various different 
mechanisms, as they are found throughout the entire coding sequence 
Fig. 1. H3F3A mutations (NM_002107.4) and H3F3B mutations (NM_005324.4). N, 1, 2, and 3 refer to the N-Helix, Helix-1, Helix-2, and Helix-3 of H3.3, respectively. 
Upper mutations are encoded by H3F3B, and lower mutations are encoded by H3F3A. Red arrows indicate mutations found in two or more unrelated patients. A few variants, 
p.N108S, p.P121R, and p.Q125R, were found in the same position in both H3F3A and H3F3B. *p.S146X is only present in an H3F3B alternate transcript not shown here.
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in different domains. To explore these mechanisms further, we used 
molecular modeling of all 37 of the variants reported here. These 
37 variants were mapped to a total of 25 loci distributed over several 
experimental structures. Eleven locations were in the structure of 
H3.3 in the nucleosome; at the sequence level, they spread from central 
positions to near the C-terminal end of H3.3. The remaining 14 loca-
tions (as well as H39, which was also present in the nucleosome) were 
mapped to different complexes between H3.3 and epigenetic regulators. 
At the sequence level, they concentrated in the N-terminal tail of H3.3.
In Fig. 2 (top), we show the location of the variants in the H3.3 
structure (for clarity, they are shown only in one H3.3 monomer) 
and (Fig. 2, bottom) a summary of the amount and type of inter-
atomic contacts at each mutation locus. Together, these data sug-
gest three broad scenarios for the variants’ impact. In the first one, 
variants are likely to disrupt the H3.3-DNA interaction because the 
native residue is involved in a large number of contacts with the DNA. 
For instance, this would be the case of p.R83C because the arginine 
residue penetrates the DNA minor groove. In the second scenario, 
variants are more likely to disrupt the histone octamer, either be-
cause they affect the intramonomer contacts of H3.3 (e.g., p.Q125R) 
or because they may alter the interaction of H3.3 with other nucleosomal 
histones (e.g., p.L48R). In the third scenario, the variants disrupt histone- 
protein binding such as the p.G90R mutation disrupting chaperone 
binding. In summary, through different mechanisms, the variants in this 
section are likely to affect the formation, the deposition, or the stability 
of the nucleosomes containing H3.3 or of the nucleosome pairing. This 
may result in a generalized loosening of chromatin structure in those 
processes requiring the incorporation of H3.3 to the nucleosome.
The available complexes between H3.3 and epigenetic regulators 
(Fig. 3A) involve short stretches of the H3.3 tail bound to sites of dif-
ferent shapes (Fig. 3B). The number of interprotein contacts at the 
variant locus may vary substantially. For example, p.H39 has 33 and 4 
contacts with SETD2 (SET Domain Containing 2, Histone Lysine 
Methyltransferase) and ZMYND11 (Zinc Finger MYND-Type Con-
taining 11) domains, respectively. We find that residues p.R8, p.S31, 
p.K36, and p.H39 are involved in more than 10 contacts across epi-
genetic regulators, suggesting that their mutation may disrupt one or 
more biologically relevant interactions. For the remaining residues, 
Table 1. Clinical findings of affected patients. Developmental delay 
was seen in varying degrees in the majority of patients; hypotonia, poor 
growth, oculomotor abnormalities, seizures, abnormal skull shape, and 
microcephaly were also commonly seen in the patients. 
33 H3F3A/13 H3F3B
25 unique H3F3A/12 unique 
H3F3B variants
3 variants in both H3F3A and B
27 males/19 females
Ages: 2 months to 32 years; 3 
deceased at 2, 10 months, and 
2.5 years
Growth
Height undergrowth 15/46 (33%)
Height overgrowth 5/46 (11%)
Weight undergrowth 4/37 (11%)
Weight overgrowth 9/37 (27%)
Microcephaly 12/46 (26%)
Development/neurologic
Achieved independent sitting 
(range: 6 months to 7 years)
33/45 (73%)
Achieved independent walking 
(range: 15 months to 8 years)
25/41 (61%)
Spoke at least one word  
(range: 12 months to 6 years)
16/43 (37%)
Progression of neurologic disease 9/46 (20%)
Brain anomalies on imaging 30/41 (73%)





Oculomotor abnormalities 25/46 (54%)
Craniofacial






Atrial septal defect 8/46 (18%)
Skeletal abnormalities 16/46 (35%)
Genital abnormalities Males 12/27 (44%)
Females 0/19 (0%)
Chronic constipation 11/45 (24%)
Fig. 2. Variant locations in the nucleosome. At the top of the figure, we show the 
structure of the nucleosome with the H3.3 variants identified with spheres; the 
H3.3 monomer carrying them is colored in dark emerald green. The coloring of 
the variants reflects the predominating interactions at each location: DNA binding 
(magenta), intramonomer contacts (light orange), and contacts with other histones 
(dark blue). The same color code is used in the histogram below the structure, 
where we show the amount of the three interaction types at each location. Note 
that we use different y axis for these interactions: The y axis to the left corresponds 
to the H3.3-DNA binding contacts (magenta bars), and the y axis to the right corresponds 
to the intramonomer (light orange bars) and intermonomer contacts (dark blue bars).
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the number of interprotein contacts decreases rapidly, limiting our 
ability to interpret mutation impact. For example, visual analysis of 
the H3.3-BRD4 (Bromodomain-containing protein 4) complex shows 
that p.A15 barely participates in the complex between both proteins; 
contact analysis shows that p.A15 has only one interatomic contact 
with Brd4. Consequently, we conclude that destabilization of the 
H3.3-Brd4 complex is an unlikely explanation for pathogenic variants. 
A general mechanism that may also be valid for variants in the histone 
tail is that they may disrupt the internucleosome packing, an import-
ant interaction in which H3 tails are involved (14). In summary, most 
of the variants in this section are likely to affect the interaction be-
tween H3.3 and epigenetic regulators with consequences that will 
depend on the biological role of each complex, or they may loosen 
chromatin structure by disrupting internucleosome packing.
Dysregulation of PTMs is distinct for each mutation
To quantify this histone PTM dysregulation, patients’ Epstein-Barr 
virus–transformed lymphoblasts (H3F3A p.A15G, H3F3A p.R17G, 
H3F3A p.T45I, H3F3B p.A29P, and H3F3B p.P121R) and primary 
fibroblasts (H3F3A p.R17G, H3F3A p.G90R, and H3F3A p.T45I) 
were obtained from patients and age- and ethnicity-matched 
controls. Histones were extracted and analyzed by nano–liquid 
chromatography–tandem mass spectrometry (LC-MS/MS) as pre-
viously described (15). This allowed for a rigorous and robust quan-
tification of histone PTM levels, providing insight into the global 
epigenetic state in each cell type. For reference, the average of the 
control lymphoblasts is depicted in Fig. 4A. Notably, analysis of co-
efficients of variation both within and across patients and controls 
revealed that the distribution of histone PTM abundances was very 
similar (Fig. 4B). Although these data show modest changes com-
pared to cells that express p.K27M- or p.K36M-mutant H3.3, which 
display a near complete loss of di- and trimethylation at K27 or K36, 
a dominant negative effect cannot be ruled out (16).
It was also observed that the overall histone PTM variation was 
slightly greater in healthy donors than in patients. Nonetheless, some 
histone PTMs were reproducibly altered when comparing patients 
to controls (Fig. 4D). Although all patients share a common phenotype 
of developmental delay, only some of them developed major congenital 
malformations (i.e., cardiac and cranial anomalies). Further study of the 
specific local dysregulation during development may lead to insights 
into the transcriptional control in these processes (i.e., cardiac and cranial 
development). In general, the magnitude of the changes was modest 
and may reflect the cell types studied and developmental timing.
The tails of H3.3 and the other H3 histones (1 to 89 amino acids) 
are identical except for residue 31, where they contain alanine and 
serine, respectively. Because peptides are generated by cleavage at 
arginine residues, it is technically impossible to assign PTMs to a 
specific H3 histone, except in the case of p.A29P. For this case, two 
PTM abundances (K27 and K36) were compared between (i) pro-
tein transcribed from the mutant p.A29P allele from patient cells, (ii) 
protein transcript from the wild-type (WT) allele from the same pa-
tient cells, and (iii) protein transcribed from the two WT alleles from a 
control (Fig. 4E). These data show notable local deregulation of PTMs 
on the mutant protein, while the WT protein from the affected patient 
shows fewer differences from the control. This is a more minor effect 
than that of published somatic oncogenic mutations; however, the dif-
ference neither confirms nor refutes a dominant negative effect (17).
Together, these data suggest that the mutant histones can be in-
corporated into the nucleosome, cause marked local deregulation of 
chromatin state, and modestly alter the global control of histone 
modifications. Of greatest interest are the local chromatin changes 
induced by mutant histone deposition: H3.3 is known to have roles 
in diverse functions, including gene expression and repression, 
chromatin stability, DNA damage repair, and differentiation. These 
mutant proteins and their aberrant PTM states could disrupt any of 
these processes to lead to the observed phenotype.
Dysregulation of transcripts associated with proliferation 
and mitosis
To evaluate which biological pathways were differentially perturbed 
in the patients, we performed RNA sequencing (RNA-seq) on fibro-
blast cells derived from patients and age- and ethnic-matched controls. 
All reads were aligned with the STAR (Spliced Transcript Alignment 
to a Reference) aligner, and Cufflinks was used for performing dif-
ferential expression analysis. In fibroblast cells (three mutations listed 
above versus three controls), the H3.3 transcripts (H3F3A and H3F3B) 
contribution to total histone H3 expression ranged from 45.1 to 72.6% 
in cases and 64.1 to 81.7% in controls (table S2). We found 323 genes 
to be differentially expressed with at least two fold changes in fibroblast 
cells (P < 0.05; table S3). Of these 323 genes, 166 were up-regulated, 
and 157 were down-regulated in cases. Differentially expressed genes 
were analyzed through David Functional Annotation Resource, and 
we found no significant biological signal in the genes with lower ex-
pression in cases but showed significant enrichment for up-regulated 
genes important in mitotic cell cycle process [Benjamini-Hochberg– 
corrected P (PBH-corrected) = 7.8 × 10−14], mitotic nuclear division 
(PBH-corrected = 5.8 × 10−10), cell division (PBH-corrected = 7.5 × 10−10), 
and many other mitosis-related processes (table S4).
To assess whether up-regulation of mitosis-related genes alters 
cells proliferation, we quantified the cellular proliferation capacity 
Fig. 3. Variant locations in H3.3-epigenetic regulator complexes. Variant locations 
could be mapped to the experimental structure of different complexes involving H3.3. 
In (A), we show the variants mapped and the gene names of the H3.3 partners in the 
corresponding complex. The same color is used for the lines originating in the same 
variant These complexes include CARM1 (Coactivator Associated Arginine Methyl-
transferase 1), ZMYND11, SETD2, NSD3 (Histone-lysine N-methyltransferase NSD3), 
MORC3 (MORC Family CW-Type Zinc Finger 3), MLLT3 (MLLT3 Super Elongation Com-
plex Subunit), KDM1B (Lysine Demethylase 1B), and BRD4. In (B), we show the total 
amount of interatomic interactions at each location, for each H3.3-epigenetic regulator 
complex. To help interpretation, we give three examples where we can see the histone 
tail (blue spheres) interacting with its partner (continuous surface in light orange); the 
histone residue at the variant location is shown in magenta.
A B
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of five patient fibroblast lines compared to six age- and sex-matched 
control fibroblast lines. Patient lines had increased cell proliferation, 
notably at 72 and 96 hours (Fig. 5A). Furthermore, all five patient 
lines shared similar viability to the six control lines (Fig. 5B). Cell 
cycle analyses showed that H3F3A p.G90R and H3F3A p.T45I had a 
similar cell cycle profile to the control lines, while H3F3A p.R17G 
showed a decrease in cells in G1 phase and an increase in cells in 
S phase compared to all three control lines (Fig. 5C).
Deficit in neural crest–derived cells in a zebrafish model
A dominant zebrafish model (p.D123N) derived from a forward genetic 
screen has been previously reported with craniofacial abnormalities, 
which were replicated in our patient cohort (Fig. 6A) (18). This hetero-
zygous missense variant replicates the dominant inheritance observed 
in humans and is only two amino acids away from a mutation iden-
tified in an affected patient (p.Q125R). Further investigation of this 
model also reveals a defect in foxd3-positive neural crest–derived 
glia, as well as melanocytes and xanthophores (Fig. 6, B to D.) The 
loss of glial cells may relate to the hypomyelination phenotype that 
is noted on the brain MRIs of over one-third of the H3.3 cohort as 
glial cells are the cell type responsible for myelination.
DISCUSSION
The discovery of missense mutations in H3.3 that cause a neuro-
developmental disorder, but not cancer, has profound implications for 
future research in histone biology. Until now, H3.3 mutations have 
only been directly linked to cancer (6). These specific mutations that 
cause a neurodevelopmental phenotype are distinct from the ones that 
cause cancer. The cancer mutations are mostly in lysines in the histone 
tail, while the only lysine mutation in our cohort is p.K36E. When this 
lysine-36 is mutated in cancer, it is mutated to methionine and not 
glutamate (19). The patient with the p.K36E mutation was 32 years old 
when he was last evaluated and still had no signs of cancer, suggesting 
that the p.K36E mutation does not lead to a strongly increased risk of 
malignancy. The only other variant in our cohort that is similar to a 
cancer-linked variant is the p.G34V mutation in H3F3B. This p.G34V 
variant in H3F3A has been shown to cause cancer only when combined 
with mutations in ATRX/DAXX (ATRX Chromatin Remodeler/Death 
Domain Associated Protein) and TP53 (TAR-DNA binding protein-43) 
(19). Understanding why the somatic p.G34V variant causes cancer, 
but germline variants cause a neurodevelopmental phenotype, is 
currently unknown and requires further study.
Notably, although the mutations are spread throughout the cod-
ing sequence, they all converge on a similar phenotype. Each muta-
tion affects different specific interactions but converge on the same 
phenotype. This suggests that the phenotype is due to dysregulation 
of H3.3 in general and not limited to a single mechanism. Molecular 
modeling revealed that mutations in the histone core likely affect 
nucleosome stability, while the mutations in the tail affect various 
protein-protein interactions. In addition to molecular modeling data, 










































Fig. 4. qMS analysis of patient samples. (A) Average profile of PTMs on canonical histones H3 and H4 across control lymphoblasts. Error bars represent SD (n = 9 donors; 
3 biological replicates each). (B) Tukey boxplot depicting the coefficients of variation of 73 modified histone H3 and H4 peptides detected by nano–LC-MS/MS (biological variance: 
across all 14 donors; patient variance: across five patients; control variance: across nine controls). (C) Average histone H3.3 protein abundance (relative to total histone H3) 
in patient and control lymphoblasts. Error bars represent SD. (D) Volcano plot demonstrating significantly altered histone PTMs in patients versus controls. Dotted line 
represents P < 0.05 significance threshold. (E) K9 and K14 PTM abundances were compared between (i) protein transcribed from the mutant p.A15G allele from patient cells, 
(ii) protein transcript from the wild-type (WT) allele from the same patient cells, and (iii) protein transcribed from the WT alleles from a control. Note that the peptide from 
amino acids 9 to 17 is indistinguishable between canonical H3 and H3.3, so the WT peptide encompasses both. (F) A29P is the only mutation occurring on the same peptide 
that distinguishes H3.3 from H3. PTMs that fall on this peptide are compared across the mutant peptide, the WT peptide from the mutant sample, and the average profile of the 
peptide from control samples. *P < 0.05, **P < 0.01, and ***P < 0.001. This shows notable local deregulation of PTMs on the mutant peptide. qMS, quantitative mass spectrometry.
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Fig. 5. Cellular dynamics of patient fibroblasts. (A) Five H3F3A/B patient fibroblast lines (H3F3B: p.G34V; H3F3A: p.R17G; H3F3A: p.G90R; H3F3A: p.T45I; and H3F3B: 
p.V117V or p.S146X in alternate transcript) demonstrated increased proliferation over six matched controls. **P < 0.005 and ***P < 0.0005. Data represent means ± SEM of 
three biological replicates using three technical replicates each. (B) The same five H3F3A/B patient fibroblasts and six controls show no major differences in cell viability. 
The data represent the means ± SEM of four biological replicates using two technical replicates each. (C) Cell cycle analysis showed differences in the S (P = 0.0127) and 
G2 (P = 0.0338) phase in the same five patient cell line compared to the six control fibroblast lines. Data represent the means ± SEM of four biological replicates using two 
technical replicates each.
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into the pathogenic mechanism of these variants. Of particular 
interest, two of the five amino acids that differentiate H3.3 from 
canonical H3 (p.S31 and p.G90) are mutated in our patient cohort. 
Both p.S31 and p.G90 are essential for proper recognition of H3.3 
by other proteins. Mutagenic analysis in yeast shows that mutations 
at p.G90 prevent H3.3-specific chaperones DAXX and UBN1 (Ubinu-
clein 1) from binding (20). The serine at position 31 is required for 
recognition of H3.3 by ZMYND11 (21). Mutations in ZMYND11 
cause an autosomal dominant neurodevelopmental phenotype similar 
to that seen in our patient cohort, including hypotonia, seizures, dys-
morphic facial features, and developmental delay (22). A second mu-
tation in our patient cohort, p.G34V, has also been shown to disrupt 
ZMYND11 binding to H3.3 (21). Other variants may disrupt histone 
octamer formation, nucleosome sliding, and chaperone binding based 
on mutagenic analysis of both H3 and H3.3  in model organisms 
(23–25). We hypothesized that additional missense mutations in our co-
hort induce epigenetic dysregulation of histone PTMs. These histones’ 
PTMs within the nucleosome affect chromatin state, mitotic initiation, 
protein-chromatin interactions, and gene expression (26–30). Specific 
PTMs of unincorporated histones also mediate chaperone recognition 
before incorporation into the nucleosome (31).
The fact that all of these mutations are heterozygous is particu-
larly noteworthy. Since there are two genes that produce H3.3, a 
heterozygous mutation in one of them means that 75% of the alleles 
are WT. A missense mutation in only 25% of the alleles is sufficient 
to cause global developmental delay, hypomyelination, cortical 
atrophy, and craniofacial anomalies. H3F3A and H3F3B are not 
expressed at the same levels so the amount of mutant protein could 
be more or less than 25% in any individual patient or tissue at any 
particular time; however, we observe the same phenotype regardless 
of whether the mutation is in H3F3A or H3F3B so a higher expression 
level from one of the genes cannot explain the severity of the pheno-
type. The fact that a single missense mutation in one allele causes 
such a severe phenotype strongly supports the importance of tight 
regulation of histones and histone PTMs. Furthermore, since our 
studies showed that the changes in the PTMs are in cis on the mutant 
H3.3 and not in trans on the WT H3.3 in the same nucleosome as is 
observed in the cancer causing mutations, the severity of the pheno-
type cannot be explained by a global dysregulation of PTMs.
Although the exact mechanism of the cellular pathology in these 
patients is unclear, H3.3 is vital for normal neurologic functioning. 
A recent study showed that H3.3 begins to replace H3.1 and H3.2 in 
postnatal mouse and human brains in a time-dependent manner and 
displaces these canonical H3 variants almost completely in adult-
hood. The important role of H3.3 over time may explain the unique 
neurodegenerative phenotype, as mice with decreased H3.3 expres-
sion in the hippocampus have impaired long-term memory (32). 
Humans with major depressive disorder have increased percentages 
of H3.3 in the nucleus accumbens, which is modulated by antide-
pressant therapy (33). This suggests that H3.3 modulators may 
represent potential targeted therapies for H3.3-related disorders and 
perhaps associated neuropsychiatric conditions in the general pop-
ulation. Future studies in patient-derived induced pluripotent stem 
cell neural cell types may further elucidate the underlying pathology.
Although these are the first germline variants associated with 
histone H3, germline variants in histones H1 and H4 with similar 
features have been reported. The overgrowth and neurodevelopmental 
delay associated with Rahman syndrome (MIM 617537) are caused 
by truncating variants in H1 Histone Family, Member E (HIST1H1E). 
(34) Recently, two specific germline variants in histone H4, which 
caused delayed growth and neurodevelopment, have been described 
in two families (35). In addition, there are many neurodevelop-
mental disorders associated with the histone lysine methylases and 
demethylases. These histone-related disorders provide a unique window 
into the role of histones in the control of development and growth.
In conclusion, we show here that heterozygous de novo missense 
variants in H3F3A and H3F3B, coding for H3.3, are associated 
with a previously undescribed phenotype of developmental delay, 
Fig. 6. Requirement of H3.3A for neural crest–derived glia and pigment cells. (A) Ventral whole-mount views of larval zebrafish heads at 5 dpf stained with Alcian Blue. 
Homozygous h3f3adb1092 mutants display complete loss of neural crest–derived jaw cartilages (n = 10/10). (B to D) In situ hybridization of zebrafish embryos for markers of 
glia (foxd3; 24 hpf), melanocytes (dct; 27 hpf), and xanthophores (xdh; 27 hpf). Homozygous h3f3adb1092 mutants injected at the one-cell stage with a control mCherry RNA 
show partial reductions in cranial glia (n = 5), melanocytes (n = 4), and xanthophores (n = 3), while those injected with dominant-negative H3f3a RNA to further reduced 
H3.3A function show complete loss of melanocytes (n = 5) and severe reductions of glia (n = 6) and xanthophores (n = 4) throughout cranial and trunk regions.
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neurodegeneration, epilepsy, facial dysmorphism, and congenital 
anomalies. The functional effects of these mutations appear to be 
different from those that are well-studied in cancer and may offer a 
target for therapy for these and other patients.
MATERIALS AND METHODS
The Institutional Review Boards of Columbia University, the Univer-
sity of Michigan, Children’s Hospital of Eastern Ontario, University 
Medical Center Hamburg-Eppendorf, and the Children’s Hospital 
of Philadelphia approved this study. Informed consent was obtained 
from all individual participants included in the study. Additional 
informed consent was obtained from all individual participants for 
whom identifying information is included in this article.
Exome and genome sequencing
Genomic DNA was extracted from whole blood from the affected chil-
dren and their parents. Exome or genome sequencing was performed 
with a variety of standard capture kits and the general assertion criteria 
for variant classification following ACMGG/AMP (American College of 
Medical Genetics and Genomics/Association for Molecular Pathology) 
guidelines (36). There were no other variants in these patients that sur-
vived filtration and analysis using either dominant or recessive models 
and could explain the phenotypes.
Patient and control fibroblast cell lines
Six healthy control cells lines that were matched to available patient 
cells for passage number, age, and sex were obtained from the Coriell 
Institute for Medical Research tissue bank. All these fibroblast samples 
were derived from skin biopsies performed either on the arm or on 
the leg of the patient. Only a portion of the patients who participated 
in our study agreed to donate cellular material, and the patient muta-
tions that were analyzed reflect the sum of the viable donations.
Histone derivatization and PTM analysis by nano–LC-MS
Histones were purified in acid as previously described by Karch et al. 
(37). Acid-extracted histones (15 to 25 g) were resuspended in 
100 mM ammonium bicarbonate (pH 8), derivatized using pro-
pionic anhydride, and digested with trypsin as previously described 
(37). The resulting histone peptides were desalted using the C18 Stage 
Tips, dried using a centrifugal evaporator, and reconstituted using 
0.1% formic acid in preparation for nano–LC-MS analysis.
Nano-LC was performed using the Thermo Fisher Scientific 
Easy nLC 1000 System equipped with a 75 m by 20  cm in-house 
packed column using Reprosil-Pur C18-AQ (3 m; Maisch GmbH, 
Germany). Buffer A was 0.1% formic acid, and buffer B was 0.1% for-
mic acid in 100% acetonitrile. Peptides were resolved using a two- step 
gradient from 0 to 26% B over 45 min and then from 26 to 98% B over 
10 min at a flow rate of 300 nl/min. The high-performance LC was 
coupled online to an Orbitrap Elite mass spectrometer operating in the 
positive mode using a Nanospray Flex ion source (Thermo Fisher Sci-
entific) at 2.40 kV. MS was performed using data-independent acquisition 
(DIA) as previously described with slight modifications (37). Briefly, 
two full MS scans [mass/charge ratio (m/z), 300 to 100) were acquired 
in the Orbitrap with a resolution of 120,000 (at 200 m/z) every 
eight DIA MS/MS events using isolation windows of 50 m/z each (e.g., 
300 to 350, 350 to 400… 650 to 700). The full MS scan is performed 
twice within the same duty cycle to allow for a more resolved defini-
tion of the precursor peak profile. MS/MS events were acquired in the 
ion trap operating in normal mode. Fragmentation was performed us-
ing collision-induced dissociation in the ion trap mass analyzer with a 
normalized collision energy of 35. Automatic gain control (AGC) tar-
get and maximum injection time were 10 × 106 and 50 ms for the full MS 
scan and 10 × 104 and 150 ms for the MS/MS scan, respectively.
Data were searched using EpiProfile. The peptide relative ratio 
was calculated using the total area under the extracted ion chro-
matograms of all peptides with the same amino acid sequence 
(including all of its modified forms) as 100%. For isobaric peptides, 
the relative ratio of two isobaric forms was estimated by averaging 
the ratio for each fragment ion with different mass between the two 
species. Two to three biological replicates were analyzed per condi-
tion, and the relative abundance of each peptide modification was 
averaged across the runs.
Western blot validations
Isolated histones were separated on a 4 to 12% NuPAGE bis-tris gel 
and transferred to a 0.2-m nitrocellulose blotting membrane. 
Membranes were blocked in TBS-T [50 mM tris-HCl (pH 7.5), 150 mM 
NaCl, and 0.1% Tween 20] containing 5% milk powder and probed 
for H3.3 (Thermo Fisher Scientific, MA5-24667; 1:5000), H3 (Abcam, 
ab1791; 1:5000), and H4 (Abcam, ab7311; 1:5000) primary antibodies 
diluted in TBS-T containing 5% milk powder. This was followed by 
anti-rabbit horseradish peroxidase (Abcam, ab99697; 1:10,000) and 
visualized using enhanced chemiluminesence prime Western blot-
ting detection chemiluminescent reagent.
RNA-seq expression analysis
RNA was extracted using the RNeasy Mini Kit (QIAGEN) on the 
six samples at the same time. Extracted RNA samples underwent 
quality control assessment using Bioanalyzer (Agilent, Santa Clara, 
CA, USA) and were quantified using NanoDrop from NanoDrop 
Technologies (Wilmington, DE, USA). RNA libraries were prepared 
using the Illumina TruSeq RNA sample prep V2 with ribosomal 
RNA depletion and were sequenced using HiSeq 2500 sequencer 
(Illumina Inc., San Diego, CA, USA) at the Center for Applied 
Genomics at the Children’s Hospital of Philadelphia per standard 
protocols (paired-end 100 base pairs). The RNA-seq data were aligned 
on the hg19 reference genome using STAR (www.encodeproject.
org/software/star/) and processed using Cufflinks (http://cole-trapnell- 
lab.github.io/cufflinks/). For each gene, we compared the expression 
levels between cases and controls. A gene was considered differentially 
expressed if the P value is less than 0.05 and fragments per kilobase of 
transcript per million mapped reads has at least twofold change. To 
identify overrepresented functional categories among genes that are 
differentially expressed, we performed annotation analysis using the 
David Functional Annotation Resource (https://david.ncifcrf.gov/). 
Multiple testing was adjusted using the Benjamini- Hochberg approach, 
and enrichment was declared if the adjusted P value is less than 0.05.
Cellular analysis
Cellular proliferation was assayed with five patients and six control 
fibroblast cell lines; they were plated at 3 × 104 cells per well and then 
were manually counted at baseline, 24, 48, 72, and 96 hours. Then, 
the means ± SEM of three biological replicates using three technical 
replicates each were analyzed. Cell viability was analyzed with three 
patients and three control fibroblast cell lines; the cells were plated 
and grown until ~80% confluent. Then, they were stained for 
annexin V/propidium iodide (PI), and fluorescence- activated cell 
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sorting (FACS) was performed on Accuri C6 (BD Biosciences). Then, 
the means ± SEM of four biological replicates using two technical 
replicates each were analyzed. Cell cycle analysis was performed with 
three patients and three control fibroblast cell lines; the cells were 
plated and grown until ~80% confluent. They were then stained for 
PI, and FACS was performed on Calibur and analyzed by FlowJo. 
Then, the means ± SEM of four biological replicates using two tech-
nical replicates each were analyzed.
Zebrafish analysis
All zebrafish experiments were approved by the University of 
Southern California Institutional Animal Care and Use Committee 
(protocol #20258). h3f3adb1092 mutants were genotyped, and control 
mCherry or dominant-negative D123N H3f3a mRNAs were prepared 
and injected at 900 ng/l into one-cell stage embryos as described 
(18). Acid-free cartilage staining with Alcian Blue was performed as 
described (38). In situ hybridization was performed with the probes 
and procedures described in (18). Images were captured on a Leica 
DM2500 compound microscope.
Computational analysis of structural location of the variants
For each H3.3 variant location, we analyzed its pattern of inter-
atomic contacts (see below) using experimental structural informa-
tion. The list of known structures was retrieved from the UniProt 
record of H3.3 (P84243). In all cases, the structure of H3.3 was in-
complete, that is, only a fragment in complex with other proteins is 
described. For each variant, we identified the Protein Data Bank 
(PDB) entries that provided information about its location. We pro-
vide a table of the PDB files used in table S5.
Computing interactions at the native locus
For each variant, we computed the network of interatomic interac-
tions of the native residue. This network was obtained following a 
simple protocol: (i) retrieve the corresponding PDB, (ii) compute 
the network of interactions for all the protein residues using Ring, 
(iii) extract the interaction data corresponding to the native residue, 
and (iv) organize these interaction data into three groups [intra-
monomer (within the same H3.3 monomer), intermonomer (between 
H3.3 monomer and other proteins), and H3.3-DNA] (39). Intra-
monomer interactions were only kept when the atoms involved 
came from residue pairs (i,j) separated by more than two residues in 
sequence, i.e., |i − j| > 2. Ring computations were executed with 
default parameters, except for “interaction type,” which was set to 
“all.” H3.3-DNA contacts were only included if their distance was 
lower than 5.5 Å.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/49/eabc9207/DC1
View/request a protocol for this paper from Bio-protocol.
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